rTMS Intervention for Hypermetria

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Moss Rehabilitation Research Institute, Elkins Park, PA
Hypermetria+1 More
Transcranial Magnetic Stimulation (TMS) - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study will determine (1) whether baseline inhibitory activity in the primary motor cortex can predict motor learning ability in individuals with cerebellar degeneration, and (2) whether modulating primary motor cortex activity with non-invasive brain stimulation alters motor learning ability in this population.

Eligible Conditions

  • Hypermetria

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Hypermetria

Study Objectives

7 Primary · 0 Secondary · Reporting Duration: Baseline

Baseline
Cortical Silent Period
International Cooperative Ataxia Rating Scale Limb Coordination Sub-Score
International Cooperative Ataxia Rating Scale Total Score
Slope of the Corticomotor Excitability Recruitment Curve
Slope of the Short-Interval Intracortical Inhibition (SICI) Recruitment Curve
Day 10
Reinforcement Learning Rate
Total Reinforcement Learning

Trial Safety

Safety Progress

1 of 3

Other trials for Hypermetria

Trial Design

1 Treatment Group

rTMS Intervention
1 of 1
Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: rTMS Intervention · No Placebo Group · N/A

rTMS Intervention
Device
Experimental Group · 1 Intervention: Transcranial Magnetic Stimulation (TMS) · Intervention Types: Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulation (TMS)
2018
Completed Phase 4
~400

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline

Trial Background

Amanda Therrien, PhD
Principal Investigator
Albert Einstein Healthcare Network
Closest Location: Moss Rehabilitation Research Institute · Elkins Park, PA
2010First Recorded Clinical Trial
0 TrialsResearching Hypermetria
3 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.